Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label, randomized, pilot study on the activity of olanzapine with or without delayed dexamenthasone versus dexamenthasone alone for the prevention of delayed nausea and vomiting in patients with gynecologic cancers receiving carboplatin and paclitaxel-based chemotherapy and guidline-directed prophylactic anti-emetics.

Trial Profile

Open label, randomized, pilot study on the activity of olanzapine with or without delayed dexamenthasone versus dexamenthasone alone for the prevention of delayed nausea and vomiting in patients with gynecologic cancers receiving carboplatin and paclitaxel-based chemotherapy and guidline-directed prophylactic anti-emetics.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olanzapine (Primary) ; Dexamethasone; Dexamethasone; Dexamethasone; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use

Most Recent Events

  • 27 Feb 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top